Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Bendamustine-ixazomib-dexamethasone combo safe, effective for RRMM

14 Aug 2019

The combination of bendamustine, ixazomib and dexamethasone (BID) is well-tolerated and effective for patients with relapsed and/or refractory multiple myeloma (RRMM), reports a recent study.

Researchers conducted an open-label, single-centre phase I/II study, testing the safety, tolerability and efficacy of BID on 28 RRMM patients (median age, 67 years; 57 percent male). At the time of data cutoff, 39 percent (n=11) of the participants had died.

The 18 survivors available for the evaluation of treatment response completed a median of four cycles. The overall response rate was 61 percent, with two patients (11 percent) showing very good partial response. Nine patients (50 percent) showed partial response and five (27 percent) achieved stable disease. Two participants (11 percent) had progressive disease.

After a median follow-up of 17 months, the overall and progression-free survival were 23.2 and 5.2 months, respectively.

In terms of safety, all patients experienced at least one adverse event of any grade that was potentially related to the study treatment. The most common haematological side effect was lymphopoenia, which was reported in 92 percent of the participants. This was followed by thrombocytopoenia (78.6 percent), leukopoenia (61 percent) and anaemia (57 percent).

Fatigue (64 percent), nausea (57 percent), diarrhoea (39 percent) and anorexia (35 percent) were the most frequently reported nonhaematological toxicities.

The most common causes of death were disease progression (55 percent) and pneumonia (27 percent). None were related to treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.